Investigational drug · Phase 2
TAK-007
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL).
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "TAK-007"
First trial start
2021
Nov 12, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TAK-007", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "TAK-007" as an intervention, largest first.
- A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)Active, not recruiting
TakedaTakeda (TAK)
NCT05020015 · 27 participants · Start Nov 12, 2021 · Primary completion Jun 16, 2024
Drug: TAK-007; Chemotherapy Agents · For: Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Sites: Birmingham, Alabama; Los Angeles, California; Washington D.C., District of Columbia · 15 sites in all
TakedaTakeda (TAK)
NCT06377228 · 0 participants · Start Jun 13, 2025 · Primary completion Sep 2, 2030
Drug: TAK-007; Chemotherapy Agents · For: Refractory Lupus Nephritis; Refractory Systemic Sclerosis
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- CAR-NK Cells in B-cell Lymphoma: A New Frontier toward Accessible and Scalable Cellular Therapy.
Duléry R, Malmberg KJ, Romee R · Blood Cancer Discov 2026
- A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.
Darrah JM, Varadarajan I, Mehta A, et al. · Blood Cancer Discov 2026
- [New therapies in metastatic castration resistant prostate cancer].
Thibault C, Massard C · Bull Cancer 2015
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Takeda.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.